How Does It Work for MASH? Rezdiffra belongs to a class of medicines called thyroid hormone receptor-beta (THR-β) agonists. In the liver, Rezdiffra attaches to the THR-β receptors. This ...

Rezdiffra (resmetirom) is a prescription drug used to help treat a specific kind of liver disease in certain situations. Rezdiffra comes as an oral tablet. Rezdiffra is used to treat nonalcoholic ...

Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

The company’s top line comprises only its product revenues. Madrigal’s commercial portfolio has one marketed drug, Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist.

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication ...

On a roll, Rezdiffra generated $137 million in sales during the first quarter of 2025, well above analysts’ average expectation of $112 million. The haul also marked a sequential increase from ...

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with ...

“Rezdiffra demonstrated broad, sustained efficacy across multiple noninvasive parameters at two years of treatment. A high, statistically significant percentage of patients with CSPH or probable ...